Nonetheless, of the two isoforms, PR-B and PR-A –a similar protein lacking the 164 initial aminoacids- PR-A is known to be the most associated to protumoral collaboration with ERa, and a Phase II clinical trial with PR modulators is underway for PR-A overexpressing breast cancers [36]. Here, S100A6 is linked to breast cancer.